Our team
Erika comes with 10+ years of experience spanning industry (Takeda Pharmaceuticals, Rare Disease), entrepreneurship (e@UBC), and academia (University of Toronto, University of British Columbia, Harvard Medical School).
With a specific interest in Rare Disease and Women’s Health, Erika looks forward to developing long-lasting RNA-based therapies for treating blood coagulation disorders using Seragene’s promising nanomedicine technology.
With a specific interest in Rare Disease and Women’s Health, Erika looks forward to developing long-lasting RNA-based therapies for treating blood coagulation disorders using Seragene’s promising nanomedicine technology.
LJ comes with 6+ years’ experience in hematological research and the development of RNA therapeutics to control blood coagulation. She has successfully led or contributed to many collaborations testing the RNA agents she developed in animal models, which are published in leading hematology journals including Blood, Journal of Thrombosis and Haemostasis, and Blood Advances.
She has helped raise > $2.5M USD for the development of RNA therapeutics for hematological applications, and is an inventor on two patents in SeraGene's IP portfolio.
She has helped raise > $2.5M USD for the development of RNA therapeutics for hematological applications, and is an inventor on two patents in SeraGene's IP portfolio.
Amy comes with 6+ years’ experience in working with interdisciplinary teams of researchers and clinicians to advance the development of RNA therapeutics for bleeding disorders.
She is the inventor of SeraGene’s two lead assets and has published her work in high impact journals including Blood and Science Translational Medicine.
Amy has secured millions of dollars of research funding from governmental sources, investment groups, and industry partners to support development of Seragene’s pipeline.
She is the inventor of SeraGene’s two lead assets and has published her work in high impact journals including Blood and Science Translational Medicine.
Amy has secured millions of dollars of research funding from governmental sources, investment groups, and industry partners to support development of Seragene’s pipeline.
Dr. Katie Badior comes to SeraGene with a specialization in therapeutic RNA and expertise in bleeding and bleeding disorders within the field of therapeutic biotechnology.
With over 10 years of experience in blood biochemistry research, she has contributed significantly to the advancement of RNA therapeutics for hematology. Katie's background in therapeutic RNA encompasses a range of modalities, including RNA interference (RNAi), and messenger RNA (mRNA) therapeutics. With a strong background in translational research,
Katie has successfully applied her expertise to both large and small animal models of bleeding and bleeding disorders. Her ability to design and execute preclinical studies has led to critical advancements in therapeutic strategies, bridging the gap between laboratory findings and clinical applications.
Katie's work has been published in prestigious journals including: Science Advances, Blood, Transfusion, and Human Genetics.
With over 10 years of experience in blood biochemistry research, she has contributed significantly to the advancement of RNA therapeutics for hematology. Katie's background in therapeutic RNA encompasses a range of modalities, including RNA interference (RNAi), and messenger RNA (mRNA) therapeutics. With a strong background in translational research,
Katie has successfully applied her expertise to both large and small animal models of bleeding and bleeding disorders. Her ability to design and execute preclinical studies has led to critical advancements in therapeutic strategies, bridging the gap between laboratory findings and clinical applications.
Katie's work has been published in prestigious journals including: Science Advances, Blood, Transfusion, and Human Genetics.
Christian is a Professor of Surgery at the Versiti Blood Research Institute and Affiliate professor, University of British Columbia with deep expertise in clotting biology.
Christian comes with 15+ years’ experience in the discovery of therapeutics targets for hematological disorders with a robust and highly resourced pre-clinical facility encompassing large and small animal models for a range of bleeding and thrombotic disorders.
Christian has extensive experience collaborating with industry and government partners (USA Department of Defense) to translate promising science into commercially viable therapeutics and technologies.
In addition to SeraGene Therapeutics, Christian is the co-founder of two other companies (NanoVation Therapeutics Inc, CoMotion Inc.) and is the inventor on over 15 patents.
Christian comes with 15+ years’ experience in the discovery of therapeutics targets for hematological disorders with a robust and highly resourced pre-clinical facility encompassing large and small animal models for a range of bleeding and thrombotic disorders.
Christian has extensive experience collaborating with industry and government partners (USA Department of Defense) to translate promising science into commercially viable therapeutics and technologies.
In addition to SeraGene Therapeutics, Christian is the co-founder of two other companies (NanoVation Therapeutics Inc, CoMotion Inc.) and is the inventor on over 15 patents.
Pieter is a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia.
Pieter and his colleagues have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have been approved by the FDA, the EMA and other regulatory bodies including Onpattro (the first RNAi drug to receive regulatory approval) and Comirnaty (Pfizer/BioNTech COVID-19 mRNA vaccine).
Pieter has also co-founded 11 biotechnology companies that now employ over 400 people, published over 400 scientific articles and is the inventor on over 100 patents. He has received many awards and honours, including the Order of Canada, the Gairdner International Award (Canada) and was elected to be a Fellow of the Royal Society (London) in 2023.
Pieter and his colleagues have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have been approved by the FDA, the EMA and other regulatory bodies including Onpattro (the first RNAi drug to receive regulatory approval) and Comirnaty (Pfizer/BioNTech COVID-19 mRNA vaccine).
Pieter has also co-founded 11 biotechnology companies that now employ over 400 people, published over 400 scientific articles and is the inventor on over 100 patents. He has received many awards and honours, including the Order of Canada, the Gairdner International Award (Canada) and was elected to be a Fellow of the Royal Society (London) in 2023.
.png)
Kaley is currently the Director of Business Development at Quark Venture, a Vancouver-based venture capital group that invests globally in health science, and is responsible for identifying and performing due diligence on potential investment opportunities.
Kaley is also currently interim CEO of Sitka Biopharma and serves on the Board of Quark Venture’s portfolio company Canary Medical. From January 2018 until September 2019, Dr. Wilson was also the CEO of ARTMS Products Inc. a global leader in the development of disruptive medical isotope production technologies. Following its seed financing, Dr. Wilson joined ARTMS to help grow the company and to implement a global sales and marketing strategy. Prior to joining Quark Venture in October 2016, Dr. Wilson was Associate Director, Partnerships, at the Centre for Drug Research and Development.
Kaley obtained her PhD at the University of British Columbia (UBC), Canada, where she worked in close collaboration with senior scientists at INEX Pharmaceuticals on the immunomodulatory activity and vaccine potential of lipid encapsulated nucleic acids.
Kaley is also currently interim CEO of Sitka Biopharma and serves on the Board of Quark Venture’s portfolio company Canary Medical. From January 2018 until September 2019, Dr. Wilson was also the CEO of ARTMS Products Inc. a global leader in the development of disruptive medical isotope production technologies. Following its seed financing, Dr. Wilson joined ARTMS to help grow the company and to implement a global sales and marketing strategy. Prior to joining Quark Venture in October 2016, Dr. Wilson was Associate Director, Partnerships, at the Centre for Drug Research and Development.
Kaley obtained her PhD at the University of British Columbia (UBC), Canada, where she worked in close collaboration with senior scientists at INEX Pharmaceuticals on the immunomodulatory activity and vaccine potential of lipid encapsulated nucleic acids.